Following fields are empty!

1
Search
2
Select
3
Submit
278
Journals
Go to Previous Page
Page 3 of 14
Go to Next Page

Request Journal

Please fill in the form to request a new journal to be added. We will review your request and add it to the Journal Guide as soon as possible.

*

Cancer Biotherapy and Radiopharmaceuticals

ISSN: 1084-9785eISSN: 1557-8852
SIGAPS Level C
Publisher: Mary Ann Liebert
Visit Publisher homepageVisit journal homepage
Cancer ResearchMedicine(all)OncologyRadiology Nuclear Medicine and imagingPharmacology

Cancer Biotherapy and Radiopharmaceuticals is a peer-reviewed journal covering cutting-edge biotherapy and innovative investigations of methods to improve cancer therapy. Includes more selective delivery of drugs, biologicals, radiopharmaceuticals, and other agents, and advances in delivery instrumentation and technology, with the aim of increasing efficacy of therapy, decreasing toxicity, and/or improving convenience of therapy.Topics include:• Pre-targeted cancer therapy• Clinical trials in cancer research• Antibody therapy and imaging• Tumor cell vaccines• Radioimmunotherapy• T-cell therapy• Molecular targeted therapy and imaging• Drug resistance.

Read more
Loading data ...
Compliant Options - Provided by Journal Checker Tool

Hybrid Journal

Go ahead and submit. Remember to select a CC BY licence to ensure compliance.

Transformative Agreement

Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.

Transformative Journal

Select the open access publishing option with a CC BY license to ensure compliance.

Full Open Access

Go ahead and submit. Remember to select a CC BY license to ensure compliance.

Self-Archiving

Following acceptance, please deposit your author accepted manuscript in a repository without embargo.

Self-Archiving using Rights Retention

Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.

Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool

Go to Journal

Cancer Chemotherapy and Pharmacology

ISSN: 0344-5704eISSN: 1432-0843
SIGAPS Level C
Publisher: Springer
Visit Publisher homepageVisit journal homepage
Cancer ResearchOncologyPharmacology (medical)PharmacologyToxicology

Cancer Chemotherapy and Pharmacology addresses a wide range of pharmacologic and oncologic concerns on both experimental and clinical levels. The primary focus of this rapid publication medium is on new anticancer agents, their experimental screening, preclinical toxicology and pharmacology, single and combined drug administration modalities, and clinical phase I, II and III trials. The journal publishes results recorded in the following areas: clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, and indications for chemotherapy in cancer treatment strategy. Cancer Chemotherapy and Pharmacology is essential reading for pharmacologists and oncologists.

Read more
Loading data ...
Compliant Options - Provided by Journal Checker Tool

Hybrid Journal

Go ahead and submit. Remember to select a CC BY licence to ensure compliance.

Transformative Agreement

Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.

Transformative Journal

Select the open access publishing option with a CC BY license to ensure compliance.

Full Open Access

Go ahead and submit. Remember to select a CC BY license to ensure compliance.

Self-Archiving

Following acceptance, please deposit your author accepted manuscript in a repository without embargo.

Self-Archiving using Rights Retention

Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.

Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool

Institutional Agreement

Les auteurs correspondants des Hospices Civils de Lyon ont la possibilité de publier leurs articles de recherches en Open Access dans cette revue. Pour bénéficier de cette prise en charge, déclarez les "Hospices Civils de Lyon" dans votre affiliation principale et utilisez votre adresse mail "@chu-lyon.fr" lors de la soumission de votre article.

L'éditeur précise les consignes suivantes à respecter lors de la soumission via sa plateforme:

  1. Utilisez votre adresse mail "@chu-lyon.fr" lors de la soumission de votre article
  2. Vérifiez que les Hospices Civils de Lyon apparaissent bien dans la zone "Institution"
  3. Liez votre ORCID à votre compte
  4. Si possible, réalisez la soumission depuis un ordinateur relié au réseau des HCL

ATTENTION:

  • Si l'éditeur vous demande de sélectionner la licence applicable, privilégiez la licence CC-BY à toutes autres.
  • L'accord porte uniquement sur les types d'articles suivants: "Article original", "Article de synthèse".
  • Veuillez noter que les types d'articles suivants ne sont pas couverts par cet accord : "Communication brève" et "Formation continue".
  • Cet accord ne concerne pas les revues Nature et BioMed Central (BMC).
  • Les articles publiés en accès ouvert immédiat au titre de l’accord peuvent être déposés dans leur version finale éditeur dans une archive ouverte, par exemple dans HAL-HCL.
  • Dans le cas des articles sous abonnement, il est permis par la Loi République numérique de déposer dans une archive ouverte le manuscrit auteur accepté d’un article et de le diffuser avec un embargo de 6 mois (sciences dures) ou 12 mois (SHS).

Si vous rencontrez des difficultés ou si vous avez des questions, contactez la Documentation Centrale sur sa.documentationcentrale@chu-lyon.fr ou au 04-72-11-29-99 (31-29-99)